Rinat Yerushalmi

5.0k total citations
11 papers, 182 citations indexed

About

Rinat Yerushalmi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Rinat Yerushalmi has authored 11 papers receiving a total of 182 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Rinat Yerushalmi's work include HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (5 papers). Rinat Yerushalmi is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (5 papers). Rinat Yerushalmi collaborates with scholars based in Israel, United States and Japan. Rinat Yerushalmi's co-authors include Caroline Speers, Ryan Woods, Scott Tyldesley, Karen A. Gelmon, Eitan Amir, Michal Sarfaty, Haim Bitterman, Hadar Goldvaser, Ariel Hammerman and Daniel Shepshelovich and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Rinat Yerushalmi

10 papers receiving 178 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rinat Yerushalmi Israel	7	139	67	50	47	31	11	182
Yizhao Xie China	9	100 0.7×	67 1.0×	46 0.9×	71 1.5×	68 2.2×	31	221
Lillian M. Smyth United States	7	92 0.7×	46 0.7×	39 0.8×	62 1.3×	28 0.9×	24	166
Míriam Arumí Spain	5	113 0.8×	80 1.2×	33 0.7×	47 1.0×	37 1.2×	13	172
Stefania Pipitone Italy	7	101 0.7×	62 0.9×	56 1.1×	48 1.0×	15 0.5×	22	175
Karen K. Mauland Norway	9	108 0.8×	48 0.7×	69 1.4×	58 1.2×	22 0.7×	13	259
George Emile France	9	114 0.8×	74 1.1×	20 0.4×	49 1.0×	19 0.6×	29	176
H. Tokiniwa Japan	8	66 0.5×	28 0.4×	41 0.8×	61 1.3×	32 1.0×	18	142
Francesca Rastelli Italy	7	116 0.8×	56 0.8×	68 1.4×	78 1.7×	14 0.5×	16	219
Ray Manneh Kopp Spain	9	69 0.5×	83 1.2×	38 0.8×	44 0.9×	33 1.1×	35	172
Christoph Suppan Austria	9	151 1.1×	48 0.7×	80 1.6×	142 3.0×	15 0.5×	32	241

Countries citing papers authored by Rinat Yerushalmi

Since Specialization

Citations

This map shows the geographic impact of Rinat Yerushalmi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rinat Yerushalmi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rinat Yerushalmi more than expected).

Fields of papers citing papers by Rinat Yerushalmi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rinat Yerushalmi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rinat Yerushalmi. The network helps show where Rinat Yerushalmi may publish in the future.

Co-authorship network of co-authors of Rinat Yerushalmi

This figure shows the co-authorship network connecting the top 25 collaborators of Rinat Yerushalmi. A scholar is included among the top collaborators of Rinat Yerushalmi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rinat Yerushalmi. Rinat Yerushalmi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Chan, Nancy, Virginia Kaklamani, Sara M. Tolaney, et al.. (2025). Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.. Journal of Clinical Oncology. 43(16_suppl). 1079–1079.

Fehm, Tanja, Francesco Cottone, Fabrice André, et al.. (2024). Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. The Lancet Oncology. 25(5). 614–625. 16 indexed citations

Fehm, Tanja, Fabrice André, Ian E. Krop, et al.. (2023). 186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC). ESMO Open. 8(1). 101375–101375. 4 indexed citations

Tsurutani, Junji, William Jacot, Toshinari Yamashita, et al.. (2023). 388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC). Annals of Oncology. 34. S342–S343. 10 indexed citations

Kuchuk, Iryna, Tzippy Shochat, Aarón Sulkes, et al.. (2021). Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. Breast Cancer Research and Treatment. 188(2). 379–387. 2 indexed citations

Goldvaser, Hadar, Daniel Shepshelovich, Rinat Yerushalmi, et al.. (2019). Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. JNCI Cancer Spectrum. 3(2). pkz033–pkz033. 16 indexed citations

Rugo, Hope S., Johannes Ettl, Sara A. Hurvitz, et al.. (2019). Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectrum. 4(1). pkz085–pkz085. 21 indexed citations

Hammerman, Ariel, Sari Greenberg‐Dotan, Ilan Feldhamer, Haim Bitterman, & Rinat Yerushalmi. (2015). Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study. PLoS ONE. 10(9). e0138229–e0138229. 9 indexed citations

Nguyen, Minh, Shuichi Miyakawa, Junichi Kato, et al.. (2015). Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. Clinical Cancer Research. 21(24). 5552–5562. 19 indexed citations

10.

Safra, Tamar, Bella Kaufman, Joel Greenberg, et al.. (2012). Abstract P5-20-06: RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy – a phase II study. Cancer Research. 72(24_Supplement). P5–20. 4 indexed citations

11.

Yerushalmi, Rinat, et al.. (2011). Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Annals of Oncology. 23(2). 338–345. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact